Literature DB >> 27158740

Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease.

Victor Kim1, Huaqing Zhao1, Aladin M Boriek2, Antonio Anzueto3, Xavier Soler4, Surya P Bhatt5, Stephen I Rennard6, Robert Wise7, Alejandro Comellas8, Joe W Ramsdell4, Gregory L Kinney9, MeiLan K Han10, Carlos H Martinez10, Andrew Yen11, Jennifer Black-Shinn12, Janos Porszasz13, Gerard J Criner1, Nicola A Hanania2, Amir Sharafkhaneh2, James D Crapo14, Barry J Make14, Edwin K Silverman15, Jeffrey L Curtis10,16.   

Abstract

RATIONALE: Chronic bronchitis is, by definition, a chronic condition, but the development and remission of this condition in cigarette smokers with or without chronic obstructive pulmonary disease (COPD) are poorly understood. Also, it is unclear how the persistence or new development of chronic bronchitis affects symptoms and outcomes.
OBJECTIVES: To ascertain the relationship between smoking status and the presence or absence of chronic bronchitis and the subsequent effects on symptoms and outcomes.
METHODS: We analyzed 1,775 current or ex-smokers with GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 0-IV COPD in phase 2 of the Genetic Epidemiology of COPD (COPDGene) Study, which included subjects after 5 years of follow-up from phase 1. We asked subjects at enrollment and at 5 years of follow-up about symptoms consistent with chronic bronchitis. We divided subjects into four groups: persistent chronic bronchitis- (negative at phase 1/negative at phase 2), resolved chronic bronchitis (positive/negative), new chronic bronchitis (negative/positive), and persistent chronic bronchitis+ (positive/positive). We analyzed respiratory symptoms, health-related quality of life, lung function, exacerbation frequency, and 6-minute walk distance.
MEASUREMENTS AND MAIN RESULTS: Compared with the persistent chronic bronchitis- group, members of the persistent chronic bronchitis+ group were more likely to have continued smoking (53.4%). Subjects with new chronic bronchitis were more likely to have resumed (6.6%) or continued smoking (45.6%), whereas subjects with resolved chronic bronchitis were more likely to have quit smoking (23.5%). Compared with the persistent chronic bronchitis- group, the other groups had a shorter 6-minute walk distance, worse lung function, greater exacerbation frequency, and worse respiratory symptoms. Modified Medical Research Council dyspnea and St. George's Respiratory Questionnaire scores worsened between phase 1 and phase 2 in subjects with new chronic bronchitis but improved in the resolved chronic bronchitis group. On multinomial logistic regression, quitting smoking conferred an odds ratio (OR) of 4.289 (95% confidence interval [CI], 2.689-6.842) for resolved chronic bronchitis, whereas resuming smoking had an OR of 4.585 (95% CI, 2.008-10.471) for new chronic bronchitis. Persistent smoking had an OR of 2.621 (95% CI, 1.677-4.096) and 5.767 (95% CI, 3.702-8.983) for subjects with new chronic bronchitis and subjects with persistent chronic bronchitis, respectively.
CONCLUSIONS: Persistent and newly developed chronic bronchitis are associated with continued or resumed smoking, greater respiratory symptoms, worse health-related quality of life, worse lung function, and greater exacerbation frequency. These findings stress the importance of repeatedly assessing chronic cough and sputum production in smokers to identify those at risk for poor outcomes.

Entities:  

Keywords:  chronic bronchitis; chronic obstructive pulmonary disease; smoking

Mesh:

Year:  2016        PMID: 27158740      PMCID: PMC5015750          DOI: 10.1513/AnnalsATS.201512-800OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  32 in total

Review 1.  Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema.

Authors:  Barbara A Forey; Alison J Thornton; Peter N Lee
Journal:  BMC Pulm Med       Date:  2011-06-14       Impact factor: 3.317

2.  Epidemiology Standardization Project (American Thoracic Society).

Authors:  B G Ferris
Journal:  Am Rev Respir Dis       Date:  1978-12

3.  The effect of smoking cessation on pulmonary function: a 30-month follow-up of two smoking cessation clinics.

Authors:  A S Buist; J M Nagy; G J Sexton
Journal:  Am Rev Respir Dis       Date:  1979-10

4.  Association between occupational exposure and lung function, respiratory symptoms, and high-resolution computed tomography imaging in COPDGene.

Authors:  Nathaniel Marchetti; Eric Garshick; Gregory L Kinney; Alex McKenzie; Douglas Stinson; Sharon M Lutz; David A Lynch; Gerard J Criner; Edwin K Silverman; James D Crapo
Journal:  Am J Respir Crit Care Med       Date:  2014-10-01       Impact factor: 21.405

5.  Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm.

Authors:  Roberto de Marco; Simone Accordini; Isa Cerveri; Angelo Corsico; Josep M Antó; Nino Künzli; Christer Janson; Jordi Sunyer; Deborah Jarvis; Susan Chinn; Paul Vermeire; Cecilie Svanes; Ursula Ackermann-Liebrich; Thorarinn Gislason; Joachim Heinrich; Bénédicte Leynaert; Françoise Neukirch; Jan P Schouten; Matthias Wjst; Peter Burney
Journal:  Am J Respir Crit Care Med       Date:  2006-09-28       Impact factor: 21.405

6.  Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers.

Authors:  B W M Willemse; N H T ten Hacken; B Rutgers; I G A T Lesman-Leegte; D S Postma; W Timens
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

7.  Longitudinal lung function decline in subjects with respiratory symptoms.

Authors:  C B Sherman; X Xu; F E Speizer; B G Ferris; S T Weiss; D W Dockery
Journal:  Am Rev Respir Dis       Date:  1992-10

8.  Chronic mucus hypersecretion in COPD and death from pulmonary infection.

Authors:  E Prescott; P Lange; J Vestbo
Journal:  Eur Respir J       Date:  1995-08       Impact factor: 16.671

9.  Changes in forced expiratory volume in 1 second over time in COPD.

Authors:  Jørgen Vestbo; Lisa D Edwards; Paul D Scanlon; Julie C Yates; Alvar Agusti; Per Bakke; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Courtney Crim; David A Lomas; William MacNee; Bruce E Miller; Edwin K Silverman; Ruth Tal-Singer; Emiel Wouters; Stephen I Rennard
Journal:  N Engl J Med       Date:  2011-09-26       Impact factor: 91.245

10.  Clinical and computed tomographic predictors of chronic bronchitis in COPD: a cross sectional analysis of the COPDGene study.

Authors:  Victor Kim; Adam Davey; Alejandro P Comellas; Meilan K Han; George Washko; Carlos H Martinez; David Lynch; Jin Hwa Lee; Edwin K Silverman; James D Crapo; Barry J Make; Gerard J Criner
Journal:  Respir Res       Date:  2014-04-27
View more
  22 in total

1.  Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.

Authors:  Beth L Laube; Kathryn A Carson; Gail Sharpless; Laura M Paulin; Nadia N Hansel
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-04-08       Impact factor: 2.849

2.  Association of birthplace and occupational exposures with chronic bronchitis in US Hispanics/Latinos, 2008-2011.

Authors:  Victor Kim; Wei Wang; David Mannino; Alejandro Diaz
Journal:  Occup Environ Med       Date:  2020-03-12       Impact factor: 4.402

3.  Chronic Bronchitis: Where Are We Now?

Authors:  Yaniv Dotan; Jennifer Y So; Victor Kim
Journal:  Chronic Obstr Pulm Dis       Date:  2019-04-09

Review 4.  Clinical Epidemiology of COPD: Insights From 10 Years of the COPDGene Study.

Authors:  Diego J Maselli; Surya P Bhatt; Antonio Anzueto; Russell P Bowler; Dawn L DeMeo; Alejandro A Diaz; Mark T Dransfield; Ashraf Fawzy; Marilyn G Foreman; Nicola A Hanania; Craig P Hersh; Victor Kim; Gregory L Kinney; Nirupama Putcha; Emily S Wan; J Michael Wells; Gloria E Westney; Kendra A Young; Edwin K Silverman; MeiLan K Han; Barry J Make
Journal:  Chest       Date:  2019-05-30       Impact factor: 9.410

5.  Chronic Bronchitis in Chronic Obstructive Pulmonary Disease. Magnifying Why Smoking Cessation Still Matters Most.

Authors:  Sharon R Rosenberg; Ravi Kalhan
Journal:  Ann Am Thorac Soc       Date:  2016-07

6.  Airway Mucin Concentration as a Marker of Chronic Bronchitis.

Authors:  Mehmet Kesimer; Amina A Ford; Agathe Ceppe; Giorgia Radicioni; Rui Cao; C William Davis; Claire M Doerschuk; Neil E Alexis; Wayne H Anderson; Ashley G Henderson; R Graham Barr; Eugene R Bleecker; Stephanie A Christenson; Christopher B Cooper; MeiLan K Han; Nadia N Hansel; Annette T Hastie; Eric A Hoffman; Richard E Kanner; Fernando Martinez; Robert Paine; Prescott G Woodruff; Wanda K O'Neal; Richard C Boucher
Journal:  N Engl J Med       Date:  2017-09-07       Impact factor: 91.245

7.  Early Endotyping: A Chance for Intervention in Chronic Obstructive Pulmonary Disease.

Authors:  Hans Petersen; Rodrigo Vazquez Guillamet; Paula Meek; Akshay Sood; Yohannes Tesfaigzi
Journal:  Am J Respir Cell Mol Biol       Date:  2018-07       Impact factor: 6.914

Review 8.  Genetic Advances in Chronic Obstructive Pulmonary Disease. Insights from COPDGene.

Authors:  Margaret F Ragland; Christopher J Benway; Sharon M Lutz; Russell P Bowler; Julian Hecker; John E Hokanson; James D Crapo; Peter J Castaldi; Dawn L DeMeo; Craig P Hersh; Brian D Hobbs; Christoph Lange; Terri H Beaty; Michael H Cho; Edwin K Silverman
Journal:  Am J Respir Crit Care Med       Date:  2019-09-15       Impact factor: 21.405

9.  Chronic bronchitis is associated with severe exacerbation and prolonged recovery period in Chinese patients with COPD: a multicenter cross-sectional study.

Authors:  Ying Liang; Yahong Chen; Rui Wu; Ming Lu; Wanzhen Yao; Jian Kang; Baiqiang Cai; Xin Zhou; Zheng Liu; Ping Chen; Dejun Sun; Jingping Zheng; Guoyang Wang; Yulin Feng; Yongjian Xu
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

10.  Structural airway imaging metrics are differentially associated with persistent chronic bronchitis.

Authors:  Surya P Bhatt; Sandeep Bodduluri; Abhilash S Kizhakke Puliyakote; Elizabeth C Oelsner; Arie Nakhmani; David A Lynch; Carla G Wilson; Spyridon Fortis; Victor Kim
Journal:  Thorax       Date:  2021-01-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.